论文部分内容阅读
慢性阻塞性肺疾病(COPD)是由气道和肺实质慢性炎症引起的气流阻塞综合征,在全球有极高的发病率和病死率。目前,COPD药物治疗仍以支气管扩张剂为主,但这些药物只能控制症状和延缓病情进展,不能改善预后。近几年随着对COPD分子和细胞生物学发病机制的进一步认识,出现了越来越多可望治疗有效的药物。这些药物为未来防治COPD提供了新的方向。
Chronic obstructive pulmonary disease (COPD) is a syndrome of airflow obstruction caused by chronic inflammation of the airways and lung parenchyma, with extremely high morbidity and mortality worldwide. Currently, COPD drug therapy is still the main bronchodilator, but these drugs can only control the symptoms and delay the progress of the disease, can not improve the prognosis. In recent years, with the further understanding of the pathogenesis of COPD molecular and cell biology, more and more drugs are expected to be effective. These drugs provide a new direction for future prevention and treatment of COPD.